Research Compound Comparison
GHK-Cu vs BPC-157
GHK-Cu and BPC-157 are two of the most studied recovery research peptides. GHK-Cu (glycine-histidine-lysine copper complex) modulates matrix metalloproteinases and collagen synthesis for ECM remodeling. BPC-157 (GEPPPGKPADDAGLV) activates VEGF and nitric oxide pathways for angiogenesis and vascular repair. Their mechanisms are complementary rather than redundant, targeting different phases of tissue repair.
| Parameter | GHK-Cu | BPC-157 |
|---|---|---|
| Category | Recovery | Recovery |
| Primary Receptor / Target | MMP modulation / ECM | VEGF / eNOS / NO |
| Half-Life | ~24–48h (topical model) | ~4 hours |
| Molecular Weight | 340 Da (tripeptide-Cu) | 1419 Da |
| HPLC Purity | ≥99.8% | ≥99.8% |
| COA | Batch-Specific | Batch-Specific |
| Price | $89 | $89 |
Mechanistic Comparison
GHK-Cu — ECM Remodeling and Collagen Synthesis
GHK-Cu is a tripeptide copper complex (Gly-His-Lys) that coordinates Cu2+ via the histidine imidazole ring. It modulates MMP-1, MMP-2, and MMP-9 to regulate ECM degradation and remodeling, while stimulating collagen and glycosaminoglycan synthesis. Microarray studies have identified modulation of over 4,000 genes. Research applications include ECM remodeling, skin biology, hair follicle biology, and wound healing pathway studies. The 100mg vial format provides significantly more research material than typical 50mg formats.
BPC-157 — Angiogenesis and Vascular Repair
BPC-157 is a 15-amino acid peptide with three consecutive proline residues providing structural rigidity and gastric acid stability — making it one of the few research peptides studied via oral administration models. It upregulates VEGF to drive angiogenesis (new blood vessel formation) and activates eNOS to produce nitric oxide for vasodilation and vascular repair. Research applications include angiogenesis modeling, tissue injury response, and recovery pathway investigations.
Why They Are Complementary
GHK-Cu targets the remodeling phase — collagen deposition and ECM architecture. BPC-157 targets the vascular phase — blood supply restoration via angiogenesis. Because they address different phases of tissue repair with non-competing mechanisms, they are frequently studied together in recovery research protocols.